Thomas Scherer

3.6k total citations
82 papers, 2.5k citations indexed

About

Thomas Scherer is a scholar working on Physiology, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Thomas Scherer has authored 82 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Physiology, 23 papers in Endocrinology, Diabetes and Metabolism and 17 papers in Molecular Biology. Recurrent topics in Thomas Scherer's work include Adipose Tissue and Metabolism (13 papers), Regulation of Appetite and Obesity (12 papers) and Liver Disease Diagnosis and Treatment (10 papers). Thomas Scherer is often cited by papers focused on Adipose Tissue and Metabolism (13 papers), Regulation of Appetite and Obesity (12 papers) and Liver Disease Diagnosis and Treatment (10 papers). Thomas Scherer collaborates with scholars based in Austria, United States and Switzerland. Thomas Scherer's co-authors include Christoph Buettner, Elizabeth Zieliński, James O’Hare, Cornelia A. Pauls, Gerhard Stemmler, Marcus Heldmann, Claudia Lindtner, Ludger Scheja, Kenichi Sakamoto and Kai Su and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Nature Communications.

In The Last Decade

Thomas Scherer

76 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Scherer Austria 24 932 533 519 514 504 82 2.5k
Alyson A. Miller Australia 33 1.1k 1.2× 643 1.2× 429 0.8× 311 0.6× 369 0.7× 53 3.3k
Alfredo Costa Italy 32 1.1k 1.2× 552 1.0× 347 0.7× 558 1.1× 174 0.3× 168 4.1k
Sebastiano Bruno Solerte Italy 32 925 1.0× 478 0.9× 1.1k 2.1× 261 0.5× 153 0.3× 72 2.9k
Petter Hedlund Sweden 39 531 0.6× 649 1.2× 1.2k 2.2× 419 0.8× 210 0.4× 160 4.4k
Virgilio Gallai Italy 40 1.3k 1.4× 687 1.3× 143 0.3× 380 0.7× 424 0.8× 132 4.7k
Anthony L. McCall United States 35 1.2k 1.2× 1.0k 1.9× 1.5k 2.9× 479 0.9× 305 0.6× 95 4.3k
Tetsuya Kakuma Japan 34 1.5k 1.6× 842 1.6× 467 0.9× 1.2k 2.3× 949 1.9× 85 4.2k
S. G. Gilbey United Kingdom 25 799 0.9× 449 0.8× 501 1.0× 548 1.1× 173 0.3× 53 2.3k
Stephanie Fulton Canada 29 1.2k 1.3× 484 0.9× 190 0.4× 1.5k 2.9× 327 0.6× 67 3.8k
Rita Peila United States 21 1.4k 1.5× 526 1.0× 515 1.0× 129 0.3× 266 0.5× 55 3.3k

Countries citing papers authored by Thomas Scherer

Since Specialization
Citations

This map shows the geographic impact of Thomas Scherer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Scherer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Scherer more than expected).

Fields of papers citing papers by Thomas Scherer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Scherer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Scherer. The network helps show where Thomas Scherer may publish in the future.

Co-authorship network of co-authors of Thomas Scherer

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Scherer. A scholar is included among the top collaborators of Thomas Scherer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Scherer. Thomas Scherer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Semmler, Georg, Hansjörg Habisch, Winfried März, et al.. (2025). Lipid Dysregulation in Tangier Disease: A Case Series and Metabolic Characterization. The Journal of Clinical Endocrinology & Metabolism. 110(7). e2146–e2156. 2 indexed citations
2.
Scherer, Thomas, et al.. (2025). Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome. The Journal of Clinical Endocrinology & Metabolism. 111(3). 721–733. 2 indexed citations
3.
Kautzky‐Willer, Alexandra, et al.. (2025). Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome. The Journal of Clinical Endocrinology & Metabolism. 110(12). 3364–3369. 5 indexed citations
4.
Strasser, Bernhard, Lukas Hingerl, J Kovarík, et al.. (2025). Feasibility of High‐Resolution Deuterium Metabolic Imaging of the Human Kidney Using Concentric Ring Trajectory Sampling at 7T. NMR in Biomedicine. 38(10). e70139–e70139. 2 indexed citations
5.
Harreiter, Jürgen, Michael Weber, Yvonne Winhofer, et al.. (2024). Sex differences in ectopic lipid deposits and cardiac function across a wide range of glycemic control: a secondary analysis. Obesity. 32(12). 2299–2309. 1 indexed citations
6.
Strasser, Bernhard, Wolfgang Bogner, Lukas Hingerl, et al.. (2024). Concentric Ring Trajectory Sampling With k‐Space Reordering Enables Assessment of Tissue‐Specific T1 and T2 Relaxation for 2H‐Labeled Substrates in the Human Brain at 7 T. NMR in Biomedicine. 38(2). e5311–e5311. 5 indexed citations
7.
Friske, Joachim, Thomas Scherer, Jana Starčuková, et al.. (2024). Deuterium Metabolic Imaging Enables the Tracing of Substrate Fluxes Through the Tricarboxylic Acid Cycle in the Liver. NMR in Biomedicine. 38(1). e5309–e5309.
8.
Friske, Joachim, et al.. (2024). Evaluation of Hepatic Glucose and Palmitic Acid Metabolism in Rodents on High‐Fat Diet Using Deuterium Metabolic Imaging. Journal of Magnetic Resonance Imaging. 61(2). 958–967. 1 indexed citations
9.
Fellinger, Paul, Georg Semmler, Martin Gajdošík, et al.. (2023). Increased GH/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism. The Journal of Clinical Endocrinology & Metabolism. 108(10). e989–e997. 7 indexed citations
10.
Strasser, Bernhard, Lukas Hingerl, Stanislav Motyka, et al.. (2023). Reproducibility of 3D MRSI for imaging human brain glucose metabolism using direct (2H) and indirect (1H) detection of deuterium labeled compounds at 7T and clinical 3T. NeuroImage. 277. 120250–120250. 15 indexed citations
11.
Bednařík, Petr, Alena Svátková, Lukas Hingerl, et al.. (2023). 1H magnetic resonance spectroscopic imaging of deuterated glucose and of neurotransmitter metabolism at 7 T in the human brain. Nature Biomedical Engineering. 7(8). 1001–1013. 22 indexed citations
12.
Scherer, Thomas, et al.. (2023). Novel approach using [18F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet induced NAFLD. Clinical Nutrition. 42(10). 1839–1848. 6 indexed citations
13.
Kranzbühler, Benedikt, Burkhardt Seifert, Birgit Helmchen, et al.. (2022). Is Regular Radiographic Upper Urinary Tract Imaging for Surveillance of Non-Muscle Invasive Bladder Cancer Justified?. Cancers. 14(22). 5586–5586.
14.
Scherer, Thomas, Kenichi Sakamoto, & Christoph Buettner. (2021). Brain insulin signalling in metabolic homeostasis and disease. Nature Reviews Endocrinology. 17(8). 468–483. 116 indexed citations
15.
Halilbasic, Emina, Martin Gajdošík, Marek Chmelík, et al.. (2021). Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorus‐31 Magnetic Resonance Spectroscopy Pilot Study. Journal of Magnetic Resonance Imaging. 55(2). 530–540. 3 indexed citations
16.
Wolf, Peter, Paul Fellinger, Patrik Krumpolec, et al.. (2020). Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition. Diabetes Care. 44(2). 541–548. 23 indexed citations
17.
Berghoff, Anna S., Angelika M. Starzer, Nicolás Ballarini, et al.. (2020). Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer. 135. 150–158. 12 indexed citations
18.
Fellinger, Paul, Peter Wolf, Patrik Krumpolec, et al.. (2020). Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly. JCI Insight. 5(5). 23 indexed citations
19.
Häckl, Martina, Clemens Fürnsinn, Martin Krššák, et al.. (2019). Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. Nature Communications. 10(1). 2717–2717. 91 indexed citations
20.
Brunmair, Barbara, Immanuel Adorjan, Miroslav Genov, et al.. (2019). Evidence that the multiflorine‐derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α 2 ‐adrenoceptors in mice. Diabetes Obesity and Metabolism. 22(3). 290–302. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alyson A. Miller Breakdown of academic impact, for papers by Alfredo Costa Breakdown of academic impact, for papers by Sebastiano Bruno Solerte Breakdown of academic impact, for papers by Petter Hedlund Breakdown of academic impact, for papers by Virgilio Gallai Breakdown of academic impact, for papers by Anthony L. McCall Breakdown of academic impact, for papers by Tetsuya Kakuma Breakdown of academic impact, for papers by S. G. Gilbey Breakdown of academic impact, for papers by Stephanie Fulton Breakdown of academic impact, for papers by Rita Peila
Rankless by CCL
2026